干扰素α-2b、低剂量阿糖胞苷及羟基脲联合治疗慢性粒细胞白血病的临床疗效分析  

Clinical efficacy of interferon α-2b, low-dose cytarabine and hydroxyurea in the treatment of chronic myelogenous leukemia

作　　者：张倩[1] ZHANG Qian(Department of Hematological Neoplasms,Central Hospital of Zibo Mining Group Co.,Ltd.,Zibo 255120,China)

机构地区：[1]淄博矿业集团有限责任公司中心医院血液肿瘤科,山东淄博255120

出　　处：《中国现代医生》2019年第10期83-85,共3页China Modern Doctor

摘　　要：目的分析干扰素α-2b、低剂量阿糖胞苷及羟基脲联合治疗慢性粒细胞白血病的临床疗效。方法选择2017年2月～2018年2月收治的慢性粒细胞白血病60例作为研究对象,随机分为观察组与对照组,各30例,两组患者入院后予抗炎、小苏打碱化尿液及别嘌呤醇降低血尿酸等治疗,观察组同时联合干扰素α-2b、低剂量阿糖胞苷及羟基脲,治疗后对比分析两组的临床疗效、白细胞、血红蛋白及血小板水平及不良反应。结果观察组患者治疗后的总有效率为93.3%,明显高于对照组,两组比较差异具有显著性(P<0.05)。观察组和对照组患者治疗前的白细胞、血红蛋白及血小板水平比较差异无显著性(P>0.05),治疗后,观察组患者的白细胞、血红蛋白及血小板水平分别较对照组显著降低,组间对比差异存在显著性(P<0.05)。结论干扰素α-2b、低剂量阿糖胞苷及羟基脲联合治疗慢性粒细胞白血病临床疗效确切,安全性好,值得广泛推广和应用。Objective To analyze the clinical efficacy of interferonα-2b,low-dose cytarabine and hydroxyurea in the treatment of chronic myelogenous leukemia.Methods Sixty patients with chronic myelogenous leukemia who were admitted from February 2017 to February 2018 were enrolled as subjects.They were randomly divided into observation group and control group,with 30 cases in each group.After admission,the patients were given anti-inflammatory treatment,soda to basalize urine and allopurinol to reduce blood uric acid.The observation group was combined with interferonα-2b,low-dose cytarabine and hydroxyurea.After treatment,the clinical efficacy,white blood cells,hemoglobin and platelet levels and adverse reactions were compared between the two groups.Results The total effective rate of the observation group after treatment was 93.3%,which was significantly higher than that of the control group.The difference between the two groups was significant(P<0.05).There were no significant differences in the levels of white blood cells(P>0.05),hemoglobin and platelets between the observation group and the control group.After treatment,the levels of white blood cells,hemoglobin and platelets in the observation group were significantly lower than those of the control group.The differences were significant(P<0.05).Conclusion The combination of interferonα-2b,low-dose cytarabine and hydroxyurea in the treatment of chronic myelogenous leukemia is clinically effective and safe,and it is worthy of widespread promotion and application.

关 键 词：慢性粒细胞白血病 干扰素Α-2B 低剂量阿糖胞苷 羟基脲 

分 类 号：R733.7[医药卫生—肿瘤]